Lee Galmor1, Rinat Bernstein-Molho1,2, Miri Sklair-Levy1,3, Dana Madoursky-Feldman3, Dov Zippel3, Yael Laitman4, Eitan Friedman5,6,7. 1. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 2. Breast Cancer Unit, Oncology Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel. 3. The Meirav High-Risk Clinic-Chaim Sheba Medical Center, Tel-Hashomer, Israel. 4. Oncogenetics Unit, Institute of Genetics, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel. 5. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. eitan.friedman@sheba.gov.il. 6. The Meirav High-Risk Clinic-Chaim Sheba Medical Center, Tel-Hashomer, Israel. eitan.friedman@sheba.gov.il. 7. Oncogenetics Unit, Institute of Genetics, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel. eitan.friedman@sheba.gov.il.
Abstract
BACKGROUND: The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female BRCA1/BRCA2 mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated. METHODS: Israeli female cancer-free BRCA1/BRCA2 mutation carriers, who were followed at the high-risk clinic at Sheba Medical Center between January 2011 and April 2020 were eligible. Univariate Cox regression and log-rank test were used to study the crude association between potential predictors and performance of RRBM. RESULTS: Overall, 427 cancer-free BRCA1 (n = 218) or BRCA2 (n = 209) mutation carriers were included. Median age at genotyping was 33.6 years (interquartile range 26.8-41.8 years), median follow-up 4.4 years (range 0.1-7.6 years). Overall, 41/427 (9.6%) participants underwent RRBM, all of them within 5 years of genotyping. Being married (HR-2.57, p = 0.017) and having a first degree relative with breast cancer (BC) (HR-2.19, p = 0.017) were positively associated with RRBM, whereas any previous benign breast biopsy was negatively associated (HR-0.48, p = 0.029) with performing RRBM. CONCLUSIONS: RRBM is still infrequently elected by Israeli BRCA1/BRCA2 mutation carriers, with married women with one relative with BC who have not undergone previous breast biopsy more likely to opt for RRBM.
BACKGROUND: The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female BRCA1/BRCA2 mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated. METHODS: Israeli female cancer-free BRCA1/BRCA2 mutation carriers, who were followed at the high-risk clinic at Sheba Medical Center between January 2011 and April 2020 were eligible. Univariate Cox regression and log-rank test were used to study the crude association between potential predictors and performance of RRBM. RESULTS: Overall, 427 cancer-free BRCA1 (n = 218) or BRCA2 (n = 209) mutation carriers were included. Median age at genotyping was 33.6 years (interquartile range 26.8-41.8 years), median follow-up 4.4 years (range 0.1-7.6 years). Overall, 41/427 (9.6%) participants underwent RRBM, all of them within 5 years of genotyping. Being married (HR-2.57, p = 0.017) and having a first degree relative with breast cancer (BC) (HR-2.19, p = 0.017) were positively associated with RRBM, whereas any previous benign breast biopsy was negatively associated (HR-0.48, p = 0.029) with performing RRBM. CONCLUSIONS: RRBM is still infrequently elected by Israeli BRCA1/BRCA2 mutation carriers, with married women with one relative with BC who have not undergone previous breast biopsy more likely to opt for RRBM.
Authors: A-B Skytte; A-M Gerdes; M K Andersen; L Sunde; K Brøndum-Nielsen; M Waldstrøm; S Kølvraa; D Crüger Journal: Clin Genet Date: 2010-01-06 Impact factor: 4.438
Authors: D Gareth R Evans; Fiona Lalloo; Linda Ashcroft; Andrew Shenton; Tara Clancy; Andrew D Baildam; Anne Brain; Penelope Hopwood; Anthony Howell Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08 Impact factor: 4.254
Authors: Y Laitman; Y Vaisman; D Feldman; L Helpman; M Gitly; S Paluch Shimon; R Berger; L Cohen; S A Narod; E Friedman Journal: Clin Genet Date: 2013-04-09 Impact factor: 4.438
Authors: L C Hartmann; T A Sellers; D J Schaid; T S Frank; C L Soderberg; D L Sitta; M H Frost; C S Grant; J H Donohue; J E Woods; S K McDonnell; C W Vockley; A Deffenbaugh; F J Couch; R B Jenkins Journal: J Natl Cancer Inst Date: 2001-11-07 Impact factor: 13.506
Authors: Nasim Mavaddat; Susan Peock; Debra Frost; Steve Ellis; Radka Platte; Elena Fineberg; D Gareth Evans; Louise Izatt; Rosalind A Eeles; Julian Adlard; Rosemarie Davidson; Diana Eccles; Trevor Cole; Jackie Cook; Carole Brewer; Marc Tischkowitz; Fiona Douglas; Shirley Hodgson; Lisa Walker; Mary E Porteous; Patrick J Morrison; Lucy E Side; M John Kennedy; Catherine Houghton; Alan Donaldson; Mark T Rogers; Huw Dorkins; Zosia Miedzybrodzka; Helen Gregory; Jacqueline Eason; Julian Barwell; Emma McCann; Alex Murray; Antonis C Antoniou; Douglas F Easton Journal: J Natl Cancer Inst Date: 2013-04-29 Impact factor: 13.506
Authors: Ellen Warner; Donald B Plewes; Kimberley A Hill; Petrina A Causer; Judit T Zubovits; Roberta A Jong; Margaret R Cutrara; Gerrit DeBoer; Martin J Yaffe; Sandra J Messner; Wendy S Meschino; Cameron A Piron; Steven A Narod Journal: JAMA Date: 2004-09-15 Impact factor: 56.272
Authors: Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson Journal: JAMA Date: 2017-06-20 Impact factor: 56.272
Authors: Kandamurugu Manickam; Adam H Buchanan; Marci L B Schwartz; Miranda L G Hallquist; Janet L Williams; Alanna Kulchak Rahm; Heather Rocha; Juliann M Savatt; Alyson E Evans; Loren M Butry; Amanda L Lazzeri; D'Andra M Lindbuchler; Carroll N Flansburg; Rosemary Leeming; Victor G Vogel; Matthew S Lebo; Heather M Mason-Suares; Derick C Hoskinson; Noura S Abul-Husn; Frederick E Dewey; John D Overton; Jeffrey G Reid; Aris Baras; Huntington F Willard; Cara Z McCormick; Sarath B Krishnamurthy; Dustin N Hartzel; Korey A Kost; Daniel R Lavage; Amy C Sturm; Lauren R Frisbie; T Nate Person; Raghu P Metpally; Monica A Giovanni; Lacy E Lowry; Joseph B Leader; Marylyn D Ritchie; David J Carey; Anne E Justice; H Lester Kirchner; W Andrew Faucett; Marc S Williams; David H Ledbetter; Michael F Murray Journal: JAMA Netw Open Date: 2018-09-07
Authors: Noura S Abul-Husn; Emily R Soper; Jacqueline A Odgis; Sinead Cullina; Dean Bobo; Arden Moscati; Jessica E Rodriguez; Ruth J F Loos; Judy H Cho; Gillian M Belbin; Sabrina A Suckiel; Eimear E Kenny Journal: Genome Med Date: 2019-12-31 Impact factor: 11.117